AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30424822 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention program (PA), including energy-restricted Mediterranean diet and behavioral support.
Number of subjects: 6059
Study 30424822 — intervention group
Group type: COMPARATOR
Intervention: Control group with Mediterranean diet recommendations without calorie restriction or PA advice.
Number of subjects: 6059
Study 26440134 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 × 4‐min high‐intensity interval training (4HIIT) at 85%‐95% of HRmax
Number of subjects: 30
Study 26440134 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 × 1‐min HIIT (1HIIT) at V˙O2max load
Number of subjects: 30
Study 26440134 — intervention group
Group type: EXPERIMENTAL
Intervention: 45‐min moderate‐intensity continuous training (MICT) at 70% of HRmax
Number of subjects: 30
Study 24140664 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 3602
Study 24140664 — intervention group
Group type: COMPARATOR
Intervention: UFH+GPI
Number of subjects: 3602
Study 22524767 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrahepatic ipsilateral portal vein branch ligation (Group A)
Number of subjects: 26
Study 22524767 — intervention group
Group type: COMPARATOR
Intervention: Suture ligation of the cut surface vessels only (Group B)
Number of subjects: 26
Study 20172688 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids levels
Number of subjects: 411
Study 20172688 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA levels
Number of subjects: 411
Study 17926440 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 419
Study 16291099 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical group
Number of subjects: 88
Study 16291099 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative group
Number of subjects: 88
Study 16291099 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical group at L4-5
Number of subjects: 88
Study 16291099 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative group at L4-5
Number of subjects: 88
Study 16291099 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical group at L5-S1
Number of subjects: 88
Study 16291099 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative group at L5-S1
Number of subjects: 88
Study 16291099 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical group central herniations at L4-5
Number of subjects: 88
Study 16291099 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative group central herniations at L4-5
Number of subjects: 88
Study 16291099 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical group central herniations at L5-S1
Number of subjects: 88
Study 16291099 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative group central herniations at L5-S1
Number of subjects: 88
Study 16291099 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical group paracentral herniations at L4-5
Number of subjects: 88
Study 16291099 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative group paracentral herniations at L4-5
Number of subjects: 88
Study 16291099 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical group paracentral herniations at L5-S1
Number of subjects: 88
Study 16291099 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative group paracentral herniations at L5-S1
Number of subjects: 88
Study 12671572 — intervention group
Group type: EXPERIMENTAL
Intervention: RIK mattress (KCI)
Number of subjects: 158
Study 12671572 — intervention group
Group type: COMPARATOR
Intervention: Nimbus 3 mattress (Huntleigh Healthcare)
Number of subjects: 158
Study 10588806 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials identified in prosthodontic journals
Number of subjects: 62
Study 10588806 — intervention group
Group type: COMPARATOR
Intervention: Screening of articles
Number of subjects: 62
Study 8786520 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (n = 63)
Number of subjects: 127
Study 8786520 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 64)
Number of subjects: 127
Study 1994935 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidoflazine
Number of subjects: 0
Study 1994935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6381019 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of a mean of 298 mg levodopa and benserazide plus 17 mg bromocriptine
Number of subjects: 125
Study 6381019 — intervention group
Group type: COMPARATOR
Intervention: Mean dosage of 444 mg levodopa and benserazide
Number of subjects: 125
Study 29941233 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil containing lipid emulsion (n = 30)
Number of subjects: 60
Study 29941233 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil containing lipid emulsion (n = 30)
Number of subjects: 60
Study 28498507 — intervention group
Group type: EXPERIMENTAL
Intervention: aPDT + ST
Number of subjects: 20
Study 28498507 — intervention group
Group type: COMPARATOR
Intervention: ST only
Number of subjects: 20
Study 27111335 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon anesthesia
Number of subjects: 220
Study 27111335 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 220
Study 27111335 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4mg
Number of subjects: 220
Study 24335227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue-type plasminogen activator (tPA) plus endovascular therapy
Number of subjects: 656
Study 24335227 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tPA therapy alone
Number of subjects: 656
Study 22494956 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg once daily
Number of subjects: 1272
Study 22494956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1272
Study 20646010 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent, low-intensity exercise (walking and cycling) for 6 months
Number of subjects: 50
Study 20646010 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 50
Study 20646010 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking
Number of subjects: 50
Study 17951501 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary inulin-type fructans
Number of subjects: 15
Study 17951501 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 15
Study 15864937 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol infusion (1 mg/kg loading dose at skin closure and 0.2 mg/kg/h postoperative infusion)
Number of subjects: 60
Study 15864937 — intervention group
Group type: COMPARATOR
Intervention: Morphine PCA alone (control group received saline infusion)
Number of subjects: 60
Study 11302351 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-based exercise counseling
Number of subjects: 355
Study 11302351 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 355
Study 9088586 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide (40 mg daily for 4 days)
Number of subjects: 8
Study 9088586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8154887 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment with 5'-DFUR at a daily oral dose of 600 mg/patient
Number of subjects: 55
Study 8154887 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent treatment with 5'-DFUR for 2 weeks at a daily oral dose of 1,200 mg/patient followed by 2 weeks of no treatment
Number of subjects: 55
Study 8154887 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment with 5'-DFUR
Number of subjects: 55
Study 8154887 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent treatment with 5'-DFUR
Number of subjects: 55
Study 8154887 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment regimens (continuous and intermittent)
Number of subjects: 55
Study 3525336 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 149
Study 3525336 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 149
Study 29806569 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand‐wrist resting orthosis
Number of subjects: 82
Study 29806569 — intervention group
Group type: COMPARATOR
Intervention: Epicondylitis bandage
Number of subjects: 82
Study 26928148 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended labor for at least 1 additional hour
Number of subjects: 78
Study 26928148 — intervention group
Group type: COMPARATOR
Intervention: Usual labor (expedited delivery via cesarean or operative vaginal delivery)
Number of subjects: 78
Study 26928148 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended labor
Number of subjects: 78
Study 26928148 — intervention group
Group type: COMPARATOR
Intervention: Usual labor
Number of subjects: 78
Study 26928148 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended labor and Usual labor
Number of subjects: 78
Study 24885545 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 120
Study 24885545 — intervention group
Group type: COMPARATOR
Intervention: Lumbar epidural analgesia (LEA)
Number of subjects: 120
Study 22910528 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1g/d
Number of subjects: 81
Study 22910528 — intervention group
Group type: COMPARATOR
Intervention: Docosahexaenoic acid (DHA) 1g/d
Number of subjects: 81
Study 22910528 — intervention group
Group type: COMPARATOR
Intervention: Placebo (coconut oil)
Number of subjects: 81
Study 20923370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 2316
Study 20923370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 2316
Study 20923370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2316
Study 18292675 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% nitrous oxide
Number of subjects: 14
Study 18292675 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide-free gas mixtures
Number of subjects: 14
Study 16936431 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg/day po) for 2 weeks before CABG
Number of subjects: 24
Study 16936431 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 24
Study 14499204 — intervention group
Group type: EXPERIMENTAL
Intervention: Primidone 250 mg/day (G 250)
Number of subjects: 113
Study 14499204 — intervention group
Group type: EXPERIMENTAL
Intervention: Primidone 750 mg/day (G 750)
Number of subjects: 113
Study 10923755 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg doses, three times)
Number of subjects: 6
Study 10923755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 9490141 — intervention group
Group type: EXPERIMENTAL
Intervention: Antireflux mechanism
Number of subjects: 70
Study 9490141 — intervention group
Group type: COMPARATOR
Intervention: Afferent tubular segment
Number of subjects: 70
Study 9490141 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 1350264 — intervention group
Group type: EXPERIMENTAL
Intervention: M27 beta marker for detecting hyperpolymorphic locus DXS255
Number of subjects: 0
Study 1350264 — intervention group
Group type: EXPERIMENTAL
Intervention: M27 beta and other related markers
Number of subjects: 0
Study 6756932 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg b.i.d. (twice daily)
Number of subjects: 103
Study 6756932 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg once daily
Number of subjects: 103
Study 6756932 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg added after 2 weeks of Metoprolol 100 mg b.i.d.
Number of subjects: 103
Study 6756932 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 200 mg b.i.d. (twice daily)
Number of subjects: 103
Study 30817733 — intervention group
Group type: EXPERIMENTAL
Intervention: MNM group
Number of subjects: 187
Study 29913292 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-level transforaminal lumbar interbody fusion (TLIF) for Group K (kyphotic alignment)
Number of subjects: 134
Study 29913292 — intervention group
Group type: COMPARATOR
Intervention: Single-level transforaminal lumbar interbody fusion (TLIF) for Group L (non-kyphotic alignment)
Number of subjects: 134
Study 29913292 — intervention group
Group type: COMPARATOR
Intervention: Preoperative condition for Group K
Number of subjects: 134
Study 29913292 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative condition for Group K
Number of subjects: 134
Study 27828712 — intervention group
Group type: EXPERIMENTAL
Intervention: T'ai chi (24-posture yang style) for 50 min, three times per week for 8 weeks
Number of subjects: 38
Study 27828712 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital rehabilitation program
Number of subjects: 38
Study 24672936 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment, needling at relative points, once daily for 5 consecutive days.
Number of subjects: 60
Study 24672936 — intervention group
Group type: COMPARATOR
Intervention: Control group received inotropic agents, preload and afterload reducing therapy, anti-infection, etc.
Number of subjects: 60
Study 22051941 — intervention group
Group type: EXPERIMENTAL
Intervention: PHEN/TPM CR 3.75/23 mg
Number of subjects: 0
Study 22051941 — intervention group
Group type: EXPERIMENTAL
Intervention: PHEN/TPM CR 15/92 mg
Number of subjects: 0
Study 22051941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19652065 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin 1.5 mg/m² 24-hour intravenous infusion once every 3 weeks (q3 weeks 24-hour)
Number of subjects: 270
Study 19652065 — intervention group
Group type: COMPARATOR
Intervention: Trabectedin 0.58 mg/m² 3-hour IV infusion every week for 3 weeks of a 4-week cycle (qwk 3-hour)
Number of subjects: 270
Study 17473123 — intervention group
Group type: EXPERIMENTAL
Intervention: Active immunization for rotavirus diarrhea as part of well child preventive care
Number of subjects: 0
Study 17473123 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic relief as indicated case by case
Number of subjects: 0
Study 17473123 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration therapy
Number of subjects: 0
Study 16803736 — intervention group
Group type: EXPERIMENTAL
Intervention: Four levels of geriatric care management
Number of subjects: 0
Study 12719050 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (i.v.) fentanyl 0.5 microg/kg before skin incision and no wound infiltration
Number of subjects: 45
Study 12719050 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound infiltration with ropivacaine 0.375%
Number of subjects: 45
Study 12719050 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound infiltration with ropivacaine 0.375% combined with fentanyl 0.5 microg/kg
Number of subjects: 45
Study 12719050 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including both infiltration groups and i.v. fentanyl)
Number of subjects: 45
Study 10389006 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 53
Study 10389006 — intervention group
Group type: COMPARATOR
Intervention: Arthrography
Number of subjects: 53
Study 8659967 — intervention group
Group type: EXPERIMENTAL
Intervention: Double gloves (method B: normal gloves inside, larger gloves outside)
Number of subjects: 32
Study 8659967 — intervention group
Group type: EXPERIMENTAL
Intervention: Double gloves (method C: larger gloves inside, normal gloves outside)
Number of subjects: 32
Study 8659967 — intervention group
Group type: EXPERIMENTAL
Intervention: Double gloves (method D: two pairs of normal size gloves)
Number of subjects: 32
Study 8659967 — intervention group
Group type: COMPARATOR
Intervention: Single gloves (control)
Number of subjects: 32
Study 1862204 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine 60 mg/day
Number of subjects: 0
Study 1862204 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine 45 mg/day
Number of subjects: 0
Study 1862204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6352278 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonantradol (0.5 mg)
Number of subjects: 108
Study 6352278 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine (25 mg)
Number of subjects: 108
Study 6352278 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonantradol (higher doses)
Number of subjects: 108
Study 31918720 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO, n=8; 65.25g fructose + 79.75g glucose, 1.8g carbohydrate/min)
Number of subjects: 14
Study 31918720 — intervention group
Group type: COMPARATOR
Intervention: Flavor-matched placebo (PLA, n=6)
Number of subjects: 14
Study 29888454 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla‐300)
Number of subjects: 241
Study 29888454 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla‐100)
Number of subjects: 241
Study 28673877 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.03μg·Kg‐1·min‐1
Number of subjects: 13
Study 28673877 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.05μg·Kg‐1·min‐1
Number of subjects: 13
Study 28673877 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.08μg·Kg‐1·min‐1
Number of subjects: 13
Study 28673877 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.1μg·Kg‐1·min‐1
Number of subjects: 13
Study 28673877 — intervention group
Group type: COMPARATOR
Intervention: NAVA
Number of subjects: 13
Study 28673877 — intervention group
Group type: COMPARATOR
Intervention: PSV
Number of subjects: 13
Study 26141671 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg twice a day)
Number of subjects: 42
Study 26141671 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 42
Study 23171069 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg
Number of subjects: 60
Study 23171069 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg
Number of subjects: 60
Study 23171069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21198803 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia family care programme
Number of subjects: 92
Study 21198803 — intervention group
Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 92
Study 18295276 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodynamic stress incontinence
Number of subjects: 0
Study 18295276 — intervention group
Group type: EXPERIMENTAL
Intervention: Detrusor overactivity
Number of subjects: 0
Study 18295276 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva leak point pressure
Number of subjects: 0
Study 18295276 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch or pubovaginal sling procedure
Number of subjects: 0
Study 16893754 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated coronary artery bypass grafting (CABG) in patients with OSAS
Number of subjects: 20
Study 16893754 — intervention group
Group type: COMPARATOR
Intervention: Matched control group (65 patients)
Number of subjects: 20
Study 12824833 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy silicone oil-RMN3 mixture (heavy silicone oil)
Number of subjects: 33
Study 11426582 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (10‐20 mg/day)
Number of subjects: 5610
Study 11426582 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 5610
Study 8693317 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospitalization phase intervention
Number of subjects: 570
Study 8693317 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital intervention (door to needle time lapse)
Number of subjects: 570
Study 1900384 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower linoleic acid diet (3.8 en%)
Number of subjects: 11
Study 1900384 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher linoleic acid diet (10.8 en%)
Number of subjects: 11
Study 1900384 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 11
Study 6829485 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg Zn daily supplement (group B)
Number of subjects: 46
Study 6829485 — intervention group
Group type: COMPARATOR
Intervention: No Zn supplement (group A)
Number of subjects: 46
Study 31797522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 161
Study 31797522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 161
Study 31797522 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 161
Study 31005386 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (20 mg/kg intravenous or intraosseous infusion over 20 min)
Number of subjects: 233
Study 31005386 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (40 mg/kg intravenous or intraosseous infusion over 5 min)
Number of subjects: 233
Study 27998036 — intervention group
Group type: EXPERIMENTAL
Intervention: Synovitis
Number of subjects: 107
Study 27998036 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent of medial synovitis
Number of subjects: 107
Study 25711400 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional collagenase Clostridium histolyticum (CCH)
Number of subjects: 492
Study 25711400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 492
Study 24357642 — intervention group
Group type: COMPARATOR
Intervention: Neutral shoe (Nike Pegasus 28)
Number of subjects: 103
Study 24357642 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial minimalist shoe (Nike Free 3.0 V2)
Number of subjects: 103
Study 24357642 — intervention group
Group type: EXPERIMENTAL
Intervention: Full minimalist shoe (Vibram 5‐Finger Bikila)
Number of subjects: 103
Study 22289234 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised WBV training (2 sessions/week for 6 weeks; 12 repetitions of 40-60s WBV per session)
Number of subjects: 31
Study 22289234 — intervention group
Group type: COMPARATOR
Intervention: Placebo vibrating platform (0.2mm amplitude)
Number of subjects: 31
Study 19249015 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 81
Study 19249015 — intervention group
Group type: COMPARATOR
Intervention: Control Interview (CI)
Number of subjects: 81
Study 17479824 — intervention group
Group type: EXPERIMENTAL
Intervention: Child care center staff intervention
Number of subjects: 298